drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00748 | DB01200 | 662 | 469 | [
"DDInter297",
"DDInter243"
] | Carbinoxamine | Bromocriptine | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as t... | Moderate | 1 | [
[
[
662,
24,
469
]
],
[
[
662,
6,
8374
],
[
8374,
45,
469
]
],
[
[
662,
21,
28898
],
[
28898,
60,
469
]
],
[
[
662,
24,
401
],
[
401,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromocriptine"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Co... | Carbinoxamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bromocriptine (Compound)
Carbinoxamine (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Bromocriptine (Compound)
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00209 | DB00436 | 352 | 323 | [
"DDInter1886",
"DDInter179"
] | Trospium | Bendroflumethiazide | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Minor | 0 | [
[
[
352,
23,
323
]
],
[
[
352,
23,
1014
],
[
1014,
1,
323
]
],
[
[
352,
21,
28921
],
[
28921,
60,
323
]
],
[
[
352,
35,
262
],
[
262,
... | [
[
[
"Trospium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bendroflumethiazide"
]
],
[
[
"Trospium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Benzthiazide"
],
[... | Trospium may cause a minor interaction that can limit clinical effects when taken with Benzthiazide and Benzthiazide (Compound) resembles Bendroflumethiazide (Compound)
Trospium (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Bendroflumethiazide (Compound)
Trospium (Compound) resemble... |
DB08865 | DB09098 | 1,593 | 98 | [
"DDInter448",
"DDInter1700"
] | Crizotinib | Somatrem | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1593,
24,
98
]
],
[
[
1593,
25,
1612
],
[
1612,
62,
98
]
],
[
[
1593,
23,
1459
],
[
1459,
23,
98
]
],
[
[
1593,
63,
671
],
[
671,
... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir... | Crizotinib may lead to a major life threatening interaction when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Somatrem
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Dolutegravir and Dolutegravir may cause ... |
DB01131 | DB01575 | 1,243 | 1,054 | [
"DDInter1531",
"DDInter1005"
] | Proguanil | Kaolin | Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, _Plasmodium falciparum_ and _Plasmodium vivax_, from reproducing once it is in the red blood cells. It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite. | Kaolin is a layered silicate mineral. Kaolin is used in ceramics, medicine, coated paper, as a food additive, in toothpaste, as a light diffusing material in white incandescent light bulbs, and in cosmetics. Until the early 1990s it was the active substance of anti-diarrhoea medicine Kaopectate. | Moderate | 1 | [
[
[
1243,
24,
1054
]
],
[
[
1243,
63,
929
],
[
929,
24,
1054
]
],
[
[
1243,
5,
11571
],
[
11571,
44,
929
],
[
929,
24,
1054
]
],
[
[
1243,... | [
[
[
"Proguanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kaolin"
]
],
[
[
"Proguanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyrimethamine"
],
[
... | Proguanil may cause a moderate interaction that could exacerbate diseases when taken with Pyrimethamine and Pyrimethamine may cause a moderate interaction that could exacerbate diseases when taken with Kaolin
Proguanil (Compound) treats malaria (Disease) and malaria (Disease) is treated by Pyrimethamine (Compound) and ... |
DB00424 | DB01021 | 19 | 674 | [
"DDInter896",
"DDInter1861"
] | Hyoscyamine | Trichlormethiazide | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Minor | 0 | [
[
[
19,
23,
674
]
],
[
[
19,
23,
1014
],
[
1014,
40,
674
]
],
[
[
19,
23,
178
],
[
178,
1,
674
]
],
[
[
19,
24,
1507
],
[
1507,
23,
... | [
[
[
"Hyoscyamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Hyoscyamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Benzthiazide"
],
... | Hyoscyamine may cause a minor interaction that can limit clinical effects when taken with Benzthiazide and Benzthiazide (Compound) resembles Trichlormethiazide (Compound)
Hyoscyamine may cause a minor interaction that can limit clinical effects when taken with Polythiazide and Polythiazide (Compound) resembles Trichlor... |
DB09098 | DB12130 | 98 | 1,017 | [
"DDInter1700",
"DDInter1094"
] | Somatrem | Lorlatinib | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate. Such discussion revolves around whether patients' natural dispo... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
98,
24,
1017
]
],
[
[
98,
62,
608
],
[
608,
23,
1017
]
],
[
[
98,
23,
1612
],
[
1612,
23,
1017
]
],
[
[
98,
64,
1101
],
[
1101,
... | [
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Somatrem",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Li... | Somatrem may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Somatrem may cause a minor interaction that can limit clinical effects when taken with Fostemsavir and Fostemsavir may c... |
DB00317 | DB08881 | 883 | 868 | [
"DDInter810",
"DDInter1925"
] | Gefitinib | Vemurafenib | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
883,
24,
868
]
],
[
[
883,
6,
8374
],
[
8374,
45,
868
]
],
[
[
883,
7,
3422
],
[
3422,
46,
868
]
],
[
[
883,
18,
8386
],
[
8386,
... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Gefitinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Gefitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Gefitinib (Compound) upregulates SATB1 (Gene) and SATB1 (Gene) is upregulated by Vemurafenib (Compound)
Gefitinib (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Vemurafenib (Compound)
Gefitinib (Com... |
DB00872 | DB01259 | 1,080 | 392 | [
"DDInter438",
"DDInter1024"
] | Conivaptan | Lapatinib | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Major | 2 | [
[
[
1080,
25,
392
]
],
[
[
1080,
6,
8374
],
[
8374,
45,
392
]
],
[
[
1080,
21,
29429
],
[
29429,
60,
392
]
],
[
[
1080,
25,
1135
],
[
1135... | [
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
]
],
[
[
"Conivaptan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lapatini... | Conivaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound)
Conivaptan (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Lapatinib (Compound)
Conivaptan may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol ... |
DB06655 | DB09082 | 5 | 659 | [
"DDInter1077",
"DDInter1934"
] | Liraglutide | Vilanterol | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
5,
24,
659
]
],
[
[
5,
63,
1220
],
[
1220,
23,
659
]
],
[
[
5,
24,
1296
],
[
1296,
63,
659
]
],
[
[
5,
63,
323
],
[
323,
24,
... | [
[
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin deglude... |
DB09073 | DB09280 | 951 | 1,604 | [
"DDInter1379",
"DDInter1101"
] | Palbociclib | Lumacaftor | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Major | 2 | [
[
[
951,
25,
1604
]
],
[
[
951,
63,
628
],
[
628,
24,
1604
]
],
[
[
951,
62,
479
],
[
479,
24,
1604
]
],
[
[
951,
63,
786
],
[
786,
... | [
[
[
"Palbociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ergometrine"
],
[
"Ergomet... | Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Ergometrine and Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Palbociclib may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donep... |
DB01357 | DB05679 | 890 | 1,683 | [
"DDInter1160",
"DDInter1907"
] | Mestranol | Ustekinumab | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
890,
24,
1683
]
],
[
[
890,
63,
1042
],
[
1042,
24,
1683
]
],
[
[
890,
64,
1101
],
[
1101,
24,
1683
]
],
[
[
890,
25,
350
],
[
350,
... | [
[
[
"Mestranol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Mestranol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
],
[... | Mestranol may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Mestranol may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may... |
DB01114 | DB04843 | 272 | 1,511 | [
"DDInter362",
"DDInter1149"
] | Chlorpheniramine | Mepenzolate | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
272,
24,
1511
]
],
[
[
272,
64,
675
],
[
675,
24,
1511
]
],
[
[
272,
24,
537
],
[
537,
24,
1511
]
],
[
[
272,
63,
1192
],
[
1192,
... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Chlorpheniramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
... | Chlorpheniramine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizi... |
DB00312 | DB01058 | 1,023 | 978 | [
"DDInter1423",
"DDInter1510"
] | Pentobarbital | Praziquantel | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis. The efficacy of praziquantel in treating parasitic flatworms infecti... | Moderate | 1 | [
[
[
1023,
24,
978
]
],
[
[
1023,
6,
8374
],
[
8374,
45,
978
]
],
[
[
1023,
21,
28680
],
[
28680,
60,
978
]
],
[
[
1023,
23,
752
],
[
752,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Praziquantel"
]
],
[
[
"Pentobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Com... | Pentobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Praziquantel (Compound)
Pentobarbital (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Praziquantel (Compound)
Pentobarbital may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cim... |
DB00691 | DB09038 | 1,058 | 1,450 | [
"DDInter1237",
"DDInter636"
] | Moexipril | Empagliflozin | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1058,
24,
1450
]
],
[
[
1058,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
1058,
24,
1486
],
[
1486,
24,
1450
]
],
[
[
1058,
24,
1455
],
[
14... | [
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[... | Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolo... |
DB01182 | DB08881 | 371 | 868 | [
"DDInter1534",
"DDInter1925"
] | Propafenone | Vemurafenib | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
371,
25,
868
]
],
[
[
371,
6,
8374
],
[
8374,
45,
868
]
],
[
[
371,
21,
29015
],
[
29015,
60,
868
]
],
[
[
371,
62,
608
],
[
608,
... | [
[
[
"Propafenone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Propafenone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemu... | Propafenone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Propafenone (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Vemurafenib (Compound)
Propafenone may cause a minor interaction that can limit clinical effects when taken with Lidocaine ... |
DB09054 | DB10276 | 384 | 1,624 | [
"DDInter905",
"DDInter1623"
] | Idelalisib | Rotavirus vaccine | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
384,
25,
1624
]
],
[
[
384,
64,
617
],
[
617,
24,
1624
]
],
[
[
384,
63,
552
],
[
552,
25,
1624
]
],
[
[
384,
24,
1583
],
[
1583,
... | [
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
],
[
"Budesonide",
... | Idelalisib may lead to a major life threatening interaction when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may... |
DB00649 | DB00911 | 231 | 458 | [
"DDInter1710",
"DDInter1811"
] | Stavudine | Tinidazole | A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Moderate | 1 | [
[
[
231,
24,
458
]
],
[
[
231,
24,
112
],
[
112,
1,
458
]
],
[
[
231,
21,
28882
],
[
28882,
60,
458
]
],
[
[
231,
24,
310
],
[
310,
... | [
[
[
"Stavudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinidazole"
]
],
[
[
"Stavudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole (Compound) resembles Tinidazole (Compound)
Stavudine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Tinidazole (Compound)
Stavud... |
DB00346 | DB09078 | 472 | 1,228 | [
"DDInter44",
"DDInter1036"
] | Alfuzosin | Lenvatinib | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
472,
24,
1228
]
],
[
[
472,
23,
112
],
[
112,
23,
1228
]
],
[
[
472,
25,
609
],
[
609,
24,
1228
]
],
[
[
472,
24,
1264
],
[
1264,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Alfuzosin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Alfuzosin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Alfuzosin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin ma... |
DB04868 | DB09330 | 478 | 985 | [
"DDInter1293",
"DDInter1352"
] | Nilotinib | Osimertinib | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
478,
25,
985
]
],
[
[
478,
63,
168
],
[
168,
23,
985
]
],
[
[
478,
62,
1247
],
[
1247,
23,
985
]
],
[
[
478,
24,
1478
],
[
1478,
... | [
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib"... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Nilotinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfa... |
DB00046 | DB00491 | 1,179 | 127 | [
"DDInter940",
"DDInter1217"
] | Insulin lispro | Miglitol | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Moderate | 1 | [
[
[
1179,
24,
127
]
],
[
[
1179,
23,
721
],
[
721,
62,
127
]
],
[
[
1179,
23,
1103
],
[
1103,
23,
127
]
],
[
[
1179,
24,
984
],
[
984,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
]
],
[
[
"Insulin lispro",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylcellulose"
],... | Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Methylcellulose and Methylcellulose may cause a minor interaction that can limit clinical effects when taken with Miglitol
Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Amcinonide ... |
DB09046 | DB12015 | 1,094 | 1,033 | [
"DDInter1201",
"DDInter53"
] | Metreleptin | Alpelisib | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
1094,
24,
1033
]
],
[
[
1094,
24,
1135
],
[
1135,
23,
1033
]
],
[
[
1094,
63,
1254
],
[
1254,
24,
1033
]
],
[
[
1094,
24,
951
],
[
951... | [
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Alpelisib
Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and In... |
DB00222 | DB13928 | 245 | 1,385 | [
"DDInter825",
"DDInter1660"
] | Glimepiride | Semaglutide | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
245,
24,
1385
]
],
[
[
245,
23,
1103
],
[
1103,
23,
1385
]
],
[
[
245,
24,
1154
],
[
1154,
24,
1385
]
],
[
[
245,
24,
1399
],
[
1399,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Glimepiride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
... | Glimepiride may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Semaglutide
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasire... |
DB00081 | DB08918 | 273 | 41 | [
"DDInter1838",
"DDInter1059"
] | Tositumomab | Levomilnacipran | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interc... | Moderate | 1 | [
[
[
273,
24,
41
]
],
[
[
273,
24,
901
],
[
901,
40,
41
]
],
[
[
273,
25,
498
],
[
498,
63,
41
]
],
[
[
273,
25,
330
],
[
330,
24,
... | [
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
... | Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Tositumomab may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate interaction that could exacerbat... |
DB04868 | DB09154 | 478 | 1,475 | [
"DDInter1293",
"DDInter1686"
] | Nilotinib | Sodium citrate | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Moderate | 1 | [
[
[
478,
24,
1475
]
],
[
[
478,
24,
263
],
[
263,
23,
1475
]
],
[
[
478,
63,
355
],
[
355,
23,
1475
]
],
[
[
478,
64,
1539
],
[
1539,
... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
],
[
... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Axitinib and Axitinib may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose m... |
DB01076 | DB06186 | 700 | 1,439 | [
"DDInter133",
"DDInter969"
] | Atorvastatin | Ipilimumab | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Moderate | 1 | [
[
[
700,
24,
1439
]
],
[
[
700,
63,
912
],
[
912,
24,
1439
]
],
[
[
700,
40,
671
],
[
671,
24,
1439
]
],
[
[
700,
24,
310
],
[
310,
... | [
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
... | Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Atorvastatin (Compound) resembles Fluvastatin (Compound) and Fluvastatin may cause a moderate ... |
DB00831 | DB11057 | 1,178 | 720 | [
"DDInter1866",
"DDInter1223"
] | Trifluoperazine | Mineral oil | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
1178,
24,
720
]
],
[
[
1178,
24,
927
],
[
927,
63,
720
]
],
[
[
1178,
24,
1151
],
[
1151,
24,
720
]
],
[
[
1178,
25,
1069
],
[
1069,
... | [
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
... | Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Sunitini... |
DB01064 | DB01359 | 1,148 | 729 | [
"DDInter987",
"DDInter1417"
] | Isoprenaline | Penbutolol | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Moderate | 1 | [
[
[
1148,
24,
729
]
],
[
[
1148,
63,
461
],
[
461,
1,
729
]
],
[
[
1148,
24,
699
],
[
699,
40,
729
]
],
[
[
1148,
6,
3576
],
[
3576,
... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
Isoprena... |
DB00520 | DB11901 | 1,358 | 913 | [
"DDInter306",
"DDInter107"
] | Caspofungin | Apalutamide | Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of th... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1358,
24,
913
]
],
[
[
1358,
24,
1320
],
[
1320,
63,
913
]
],
[
[
1358,
63,
322
],
[
322,
24,
913
]
],
[
[
1358,
24,
1040
],
[
1040,
... | [
[
[
"Caspofungin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Caspofungin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
... | Caspofungin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Caspofungin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubi... |
DB09564 | DB14509 | 1,296 | 1,399 | [
"DDInter930",
"DDInter1081"
] | Insulin degludec | Lithium carbonate | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
1296,
24,
1399
]
],
[
[
1296,
63,
964
],
[
964,
23,
1399
]
],
[
[
1296,
24,
1385
],
[
1385,
24,
1399
]
],
[
[
1296,
63,
820
],
[
820,
... | [
[
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycl... | Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Se... |
DB00782 | DB01227 | 1,123 | 1,301 | [
"DDInter1535",
"DDInter1043"
] | Propantheline | Levacetylmethadol | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Moderate | 1 | [
[
[
1123,
24,
1301
]
],
[
[
1123,
63,
494
],
[
494,
1,
1301
]
],
[
[
1123,
40,
11241
],
[
11241,
1,
1301
]
],
[
[
1123,
24,
1511
],
[
1511... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
... | Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Levacetylmethadol (Compound)
Propantheline (Compound) resembles Isopropamide (Compound) and Isopropamide (Compound) resembles Levacetylmethadol (Compound)
Propantheline may ca... |
DB00682 | DB12887 | 126 | 1,598 | [
"DDInter1951",
"DDInter1750"
] | Warfarin | Tazemetostat | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
126,
24,
1598
]
],
[
[
126,
62,
168
],
[
168,
23,
1598
]
],
[
[
126,
24,
985
],
[
985,
24,
1598
]
],
[
[
126,
64,
888
],
[
888,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
... | Warfarin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib... |
DB00001 | DB00569 | 1,578 | 553 | [
"DDInter1037",
"DDInter775"
] | Lepirudin | Fondaparinux | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Major | 2 | [
[
[
1578,
25,
553
]
],
[
[
1578,
23,
539
],
[
539,
62,
553
]
],
[
[
1578,
24,
972
],
[
972,
63,
553
]
],
[
[
1578,
24,
1416
],
[
1416,
... | [
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
]
],
[
[
"Lepirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
... | Lepirudin may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Fondaparinux
Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate and Cholin... |
DB00593 | DB06168 | 1,464 | 1,531 | [
"DDInter695",
"DDInter281"
] | Ethosuximide | Canakinumab | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
1464,
24,
1531
]
],
[
[
1464,
24,
1476
],
[
1476,
63,
1531
]
],
[
[
1464,
24,
1213
],
[
1213,
24,
1531
]
],
[
[
1464,
63,
58
],
[
58,
... | [
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
... | Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Da... |
DB00531 | DB00675 | 450 | 888 | [
"DDInter456",
"DDInter1744"
] | Cyclophosphamide | Tamoxifen | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Moderate | 1 | [
[
[
450,
24,
888
]
],
[
[
450,
6,
4973
],
[
4973,
45,
888
]
],
[
[
450,
18,
4729
],
[
4729,
57,
888
]
],
[
[
450,
21,
28701
],
[
28701,
... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Cyclophosphamide",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Co... | Cyclophosphamide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Tamoxifen (Compound)
Cyclophosphamide (Compound) downregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) is downregulated by Tamoxifen (Compound)
Cyclophosphamide (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Ta... |
DB00780 | DB09472 | 551 | 1,383 | [
"DDInter1440",
"DDInter1693"
] | Phenelzine | Sodium sulfate | Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name o... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
551,
24,
1383
]
],
[
[
551,
24,
1311
],
[
1311,
24,
1383
]
],
[
[
551,
75,
1466
],
[
1466,
24,
1383
]
],
[
[
551,
25,
1133
],
[
1133,
... | [
[
[
"Phenelzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Phenelzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
... | Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Phenelzine (Compound) resembles Phenylpropanolamine (Compound) and Phenelzine may lead to a major li... |
DB09280 | DB13874 | 1,604 | 1,501 | [
"DDInter1101",
"DDInter639"
] | Lumacaftor | Enasidenib | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. Patients eligible ... | Moderate | 1 | [
[
[
1604,
24,
1501
]
],
[
[
1604,
64,
1463
],
[
1463,
24,
1501
]
],
[
[
1604,
25,
1180
],
[
1180,
24,
1501
]
],
[
[
1604,
25,
829
],
[
829... | [
[
[
"Lumacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enasidenib"
]
],
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lovastatin"
],
[
"Lovastatin... | Lumacaftor may lead to a major life threatening interaction when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Lumacaftor may lead to a major life threatening interaction when taken with Rimegepant and Rimegepant may cause a moderate inte... |
DB00468 | DB00867 | 1,424 | 1,052 | [
"DDInter1557",
"DDInter1606"
] | Quinine | Ritodrine | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Adrenergic beta-agonist used to control premature labor. | Moderate | 1 | [
[
[
1424,
24,
1052
]
],
[
[
1424,
24,
1220
],
[
1220,
62,
1052
]
],
[
[
1424,
24,
1148
],
[
1148,
63,
1052
]
],
[
[
1424,
63,
245
],
[
245... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Ritodrine
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isopren... |
DB00959 | DB14711 | 1,486 | 779 | [
"DDInter1191",
"DDInter1680"
] | Methylprednisolone | Smallpox (Vaccinia) Vaccine, Live | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
1486,
25,
779
]
],
[
[
1486,
64,
1064
],
[
1064,
25,
779
]
],
[
[
1486,
24,
478
],
[
478,
25,
779
]
],
[
[
1486,
25,
1377
],
[
1377,
... | [
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],... | Methylprednisolone may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib an... |
DB00557 | DB08868 | 252 | 1,011 | [
"DDInter895",
"DDInter737"
] | Hydroxyzine | Fingolimod | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
252,
25,
1011
]
],
[
[
252,
6,
12523
],
[
12523,
45,
1011
]
],
[
[
252,
21,
28766
],
[
28766,
60,
1011
]
],
[
[
252,
23,
112
],
[
112,... | [
[
[
"Hydroxyzine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Hydroxyzine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fingo... | Hydroxyzine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Hydroxyzine (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Fingolimod (Compound)
Hydroxyzine may cause a minor interaction that can limit clinical effects when taken with Metronidazole ... |
DB01017 | DB09146 | 1,669 | 489 | [
"DDInter1224",
"DDInter978"
] | Minocycline | Iron sucrose | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, ir... | Moderate | 1 | [
[
[
1669,
24,
489
]
],
[
[
1669,
24,
260
],
[
260,
63,
489
]
],
[
[
1669,
63,
954
],
[
954,
24,
489
]
],
[
[
1669,
40,
1572
],
[
1572,
... | [
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous sulfate anhydro... | Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Ferrous sulfate anhydrous and Ferrous sulfate anhydrous may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Minocycline may cause a moderate interaction that could exacerbate diseases whe... |
DB14762 | DB14783 | 994 | 287 | [
"DDInter1602",
"DDInter574"
] | Risankizumab | Diroximel fumarate | Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
994,
24,
287
]
],
[
[
994,
63,
599
],
[
599,
24,
287
]
],
[
[
994,
64,
1510
],
[
1510,
25,
287
]
],
[
[
994,
25,
676
],
[
676,
6... | [
[
[
"Risankizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Risankizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
... | Risankizumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Risankizumab may lead to a major life threatening interaction when taken with Teriflunomide and Teri... |
DB00323 | DB01233 | 1,062 | 1,311 | [
"DDInter1829",
"DDInter1197"
] | Tolcapone | Metoclopramide | Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
1062,
24,
1311
]
],
[
[
1062,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
1062,
24,
649
],
[
649,
63,
1311
]
],
[
[
1062,
24,
662
],
[
662... | [
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Tolcapone",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is ... | Tolcapone (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Met... |
DB00250 | DB00916 | 10 | 112 | [
"DDInter475",
"DDInter1202"
] | Dapsone | Metronidazole | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Moderate | 1 | [
[
[
10,
24,
112
]
],
[
[
10,
24,
458
],
[
458,
40,
112
]
],
[
[
10,
6,
3486
],
[
3486,
45,
112
]
],
[
[
10,
21,
29547
],
[
29547,
60... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinidazole"
],
[
... | Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole and Tinidazole (Compound) resembles Metronidazole (Compound)
Dapsone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Metronidazole (Compound)
Dapsone (Compound) causes Skin exfoliation (Side Effect) and Skin ... |
DB00085 | DB00881 | 639 | 954 | [
"DDInter1384",
"DDInter1554"
] | Pancrelipase | Quinapril | Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010. For further informa... | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Moderate | 1 | [
[
[
639,
24,
954
]
],
[
[
639,
24,
1117
],
[
1117,
62,
954
]
],
[
[
639,
24,
428
],
[
428,
63,
954
]
],
[
[
639,
24,
1117
],
[
1117,
... | [
[
[
"Pancrelipase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
],
[
[
"Pancrelipase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
... | Pancrelipase may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate and Sodium bicarbonate may cause a minor interaction that can limit clinical effects when taken with Quinapril
Pancrelipase may cause a moderate interaction that could exacerbate diseases when taken with Ferr... |
DB01254 | DB14881 | 1,213 | 180 | [
"DDInter484",
"DDInter1329"
] | Dasatinib | Oliceridine | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
1213,
24,
180
]
],
[
[
1213,
62,
112
],
[
112,
23,
180
]
],
[
[
1213,
63,
401
],
[
401,
24,
180
]
],
[
[
1213,
24,
1094
],
[
1094,
... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Dasatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Dasatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Pro... |
DB00451 | DB09293 | 542 | 116 | [
"DDInter1064",
"DDInter954"
] | Levothyroxine | Iodide I-131 | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Moderate | 1 | [
[
[
542,
24,
116
]
],
[
[
542,
24,
126
],
[
126,
24,
116
]
],
[
[
542,
40,
1152
],
[
1152,
24,
116
]
],
[
[
542,
24,
33
],
[
33,
25,... | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
... | Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Levothyroxine (Compound) resembles Liothyronine (Compound) and Liothyronine may cause a moderate interaction th... |
DB04861 | DB09065 | 1,592 | 760 | [
"DDInter1271",
"DDInter424"
] | Nebivolol | Cobicistat | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
1592,
24,
760
]
],
[
[
1592,
24,
1374
],
[
1374,
23,
760
]
],
[
[
1592,
24,
868
],
[
868,
24,
760
]
],
[
[
1592,
63,
870
],
[
870,
... | [
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
... | Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemuraf... |
DB00282 | DB01172 | 641 | 416 | [
"DDInter1383",
"DDInter1004"
] | Pamidronic acid | Kanamycin | Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid]. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as [ibandronic acid], [zoledronic ... | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Moderate | 1 | [
[
[
641,
24,
416
]
],
[
[
641,
21,
29196
],
[
29196,
60,
416
]
],
[
[
641,
24,
712
],
[
712,
63,
416
]
],
[
[
641,
1,
1485
],
[
1485,
... | [
[
[
"Pamidronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Pamidronic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side ... | Pamidronic acid (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Kanamycin (Compound)
Pamidronic acid may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may cause a moderate interaction that could exacerbate diseases when tak... |
DB00782 | DB00813 | 1,123 | 704 | [
"DDInter1535",
"DDInter722"
] | Propantheline | Fentanyl | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Moderate | 1 | [
[
[
1123,
24,
704
]
],
[
[
1123,
63,
194
],
[
194,
40,
704
]
],
[
[
1123,
24,
543
],
[
543,
1,
704
]
],
[
[
1123,
24,
1322
],
[
1322,
... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
],
... | Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin and Darifenacin (Compound) resembles Fentanyl (Compound)
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide (Compound) resembles Fentanyl (Compou... |
DB01263 | DB11979 | 859 | 1,320 | [
"DDInter1494",
"DDInter625"
] | Posaconazole | Elagolix | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Major | 2 | [
[
[
859,
25,
1320
]
],
[
[
859,
63,
168
],
[
168,
23,
1320
]
],
[
[
859,
25,
1297
],
[
1297,
24,
1320
]
],
[
[
859,
63,
79
],
[
79,
... | [
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elagolix"
]
],
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezom... | Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Posaconazole may lead to a major life threatening interaction when taken with Osilodrostat and Osilodrostat may ca... |
DB00279 | DB01377 | 1,152 | 1,283 | [
"DDInter1074",
"DDInter1119"
] | Liothyronine | Magnesium oxide | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Moderate | 1 | [
[
[
1152,
24,
1283
]
],
[
[
1152,
23,
461
],
[
461,
23,
1283
]
],
[
[
1152,
24,
1252
],
[
1252,
23,
1283
]
],
[
[
1152,
24,
1482
],
[
1482... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Timolol"
],
... | Liothyronine may cause a minor interaction that can limit clinical effects when taken with Timolol and Timolol may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin ma... |
DB00603 | DB11828 | 303 | 1,406 | [
"DDInter1137",
"DDInter1281"
] | Medroxyprogesterone acetate | Neratinib | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Moderate | 1 | [
[
[
303,
24,
1406
]
],
[
[
303,
24,
392
],
[
392,
24,
1406
]
],
[
[
303,
23,
14
],
[
14,
24,
1406
]
],
[
[
303,
24,
1375
],
[
1375,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Medroxyprogesterone acetate may cause a minor interaction that can limit clinical effects when tak... |
DB01073 | DB11989 | 1,488 | 1,434 | [
"DDInter745",
"DDInter183"
] | Fludarabine | Benznidazole | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Moderate | 1 | [
[
[
1488,
24,
1434
]
],
[
[
1488,
24,
788
],
[
788,
24,
1434
]
],
[
[
1488,
25,
375
],
[
375,
24,
1434
]
],
[
[
1488,
24,
148
],
[
148,
... | [
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
... | Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Fludarabine may lead to a major life threatening interaction when taken with Certolizumab pegol and Certo... |
DB01143 | DB01324 | 923 | 178 | [
"DDInter65",
"DDInter1490"
] | Amifostine | Polythiazide | A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
923,
24,
178
]
],
[
[
923,
63,
674
],
[
674,
40,
178
]
],
[
[
923,
21,
29232
],
[
29232,
60,
178
]
],
[
[
923,
63,
1061
],
[
1061,
... | [
[
[
"Amifostine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Amifostine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
]... | Amifostine may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Amifostine (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Polythiazide (Compound)
Amifostine may cause a m... |
DB01233 | DB01563 | 1,311 | 680 | [
"DDInter1197",
"DDInter349"
] | Metoclopramide | Chloral hydrate | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | A hypnotic and sedative used in the treatment of insomnia. The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments. It is no longer considered useful as an anti-anxiety medication. | Moderate | 1 | [
[
[
1311,
24,
680
]
],
[
[
1311,
63,
272
],
[
272,
24,
680
]
],
[
[
1311,
64,
593
],
[
593,
24,
680
]
],
[
[
1311,
24,
1609
],
[
1609,
... | [
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloral hydrate"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorphenirami... | Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chloral hydrate
Metoclopramide may lead to a major life threatening interaction when taken with Bupropion a... |
DB00704 | DB08827 | 267 | 990 | [
"DDInter1263",
"DDInter1085"
] | Naltrexone | Lomitapide | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
267,
25,
990
]
],
[
[
267,
6,
4973
],
[
4973,
45,
990
]
],
[
[
267,
21,
29441
],
[
29441,
60,
990
]
],
[
[
267,
24,
1135
],
[
1135,
... | [
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Naltrexone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Lomitapid... | Naltrexone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lomitapide (Compound)
Naltrexone (Compound) causes White blood cell count increased (Side Effect) and White blood cell count increased (Side Effect) is caused by Lomitapide (Compound)
Naltrexone may cause a moderate interaction that could exacerbate ... |
DB00678 | DB11921 | 240 | 1,019 | [
"DDInter1095",
"DDInter492"
] | Losartan | Deflazacort | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough simila... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
240,
24,
1019
]
],
[
[
240,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
240,
24,
629
],
[
629,
24,
1019
]
],
[
[
240,
40,
217
],
[
217,
... | [
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
... | Losartan may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Losartan may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus ma... |
DB00026 | DB11248 | 1,184 | 1,193 | [
"DDInter94",
"DDInter1965"
] | Anakinra | Zinc gluconate | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA . It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and wi... | Minor | 0 | [
[
[
1184,
23,
1193
]
],
[
[
1184,
24,
1096
],
[
1096,
23,
1193
]
],
[
[
1184,
25,
725
],
[
725,
62,
1193
]
],
[
[
1184,
24,
270
],
[
270,
... | [
[
[
"Anakinra",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Anakinra may lead to a major life threatening interaction when taken with Satralizumab and Satrali... |
DB01169 | DB04844 | 57 | 843 | [
"DDInter120",
"DDInter1778"
] | Arsenic trioxide | Tetrabenazine | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Major | 2 | [
[
[
57,
25,
843
]
],
[
[
57,
63,
479
],
[
479,
40,
843
]
],
[
[
57,
62,
112
],
[
112,
23,
843
]
],
[
[
57,
64,
1555
],
[
1555,
24,
... | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
... | Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interact... |
DB00515 | DB01098 | 589 | 14 | [
"DDInter387",
"DDInter1622"
] | Cisplatin | Rosuvastatin | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Moderate | 1 | [
[
[
589,
24,
14
]
],
[
[
589,
24,
671
],
[
671,
24,
14
]
],
[
[
589,
6,
17404
],
[
17404,
45,
14
]
],
[
[
589,
21,
30252
],
[
30252,
... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Cisplatin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Rosuvastatin (Compound)
Cisplatin (Compo... |
DB00524 | DB00910 | 811 | 1,041 | [
"DDInter1199",
"DDInter1394"
] | Metolazone | Paricalcitol | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | Moderate | 1 | [
[
[
811,
24,
1041
]
],
[
[
811,
63,
386
],
[
386,
25,
1041
]
],
[
[
811,
24,
1098
],
[
1098,
64,
1041
]
],
[
[
811,
21,
28785
],
[
28785,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paricalcitol"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholecalciferol"
],
... | Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Cholecalciferol and Cholecalciferol may lead to a major life threatening interaction when taken with Paricalcitol
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Dihydrotachysterol and D... |
DB01263 | DB05351 | 859 | 101 | [
"DDInter1494",
"DDInter519"
] | Posaconazole | Dexlansoprazole | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of , which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generatio... | Moderate | 1 | [
[
[
859,
24,
101
]
],
[
[
859,
25,
1069
],
[
1069,
23,
101
]
],
[
[
859,
25,
263
],
[
263,
62,
101
]
],
[
[
859,
63,
609
],
[
609,
2... | [
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"V... | Posaconazole may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Posaconazole may lead to a major life threatening interaction when taken with Axitinib and Axitinib may cause a minor inte... |
DB01174 | DB08899 | 697 | 129 | [
"DDInter1442",
"DDInter649"
] | Phenobarbital | Enzalutamide | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
697,
24,
129
]
],
[
[
697,
6,
8374
],
[
8374,
45,
129
]
],
[
[
697,
21,
28921
],
[
28921,
60,
129
]
],
[
[
697,
63,
112
],
[
112,
... | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Phenobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Com... | Phenobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Phenobarbital (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Enzalutamide (Compound)
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Metron... |
DB00188 | DB01166 | 168 | 477 | [
"DDInter222",
"DDInter379"
] | Bortezomib | Cilostazol | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
168,
24,
477
]
],
[
[
168,
6,
8374
],
[
8374,
45,
477
]
],
[
[
168,
7,
4450
],
[
4450,
46,
477
]
],
[
[
168,
7,
6509
],
[
6509,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Bortezomib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Bortezomib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Bortezomib (Compound) upregulates RRP8 (Gene) and RRP8 (Gene) is upregulated by Cilostazol (Compound)
Bortezomib (Compound) upregulates EIF5 (Gene) and EIF5 (Gene) is downregulated by Cilostazol (Compound)
Bortezomib (Compound... |
DB00035 | DB01009 | 1,314 | 935 | [
"DDInter507",
"DDInter1009"
] | Desmopressin | Ketoprofen | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Moderate | 1 | [
[
[
1314,
24,
935
]
],
[
[
1314,
24,
1274
],
[
1274,
24,
935
]
],
[
[
1314,
24,
1263
],
[
1263,
1,
935
]
],
[
[
1314,
6,
10522
],
[
10522,... | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
... | Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac and... |
DB00679 | DB01105 | 684 | 222 | [
"DDInter1796",
"DDInter1665"
] | Thioridazine | Sibutramine | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
684,
24,
222
]
],
[
[
684,
18,
9385
],
[
9385,
57,
222
]
],
[
[
684,
7,
8386
],
[
8386,
57,
222
]
],
[
[
684,
21,
28852
],
[
28852,
... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Thioridazine",
"{u} (Compound) downregulates {v} (Gene)",
"MRPL19"
],
[
"MRPL19",
"{u} (Gene) is downregulate... | Thioridazine (Compound) downregulates MRPL19 (Gene) and MRPL19 (Gene) is downregulated by Sibutramine (Compound)
Thioridazine (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Sibutramine (Compound)
Thioridazine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused b... |
DB08901 | DB12887 | 1,468 | 1,598 | [
"DDInter1492",
"DDInter1750"
] | Ponatinib | Tazemetostat | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
1468,
24,
1598
]
],
[
[
1468,
63,
168
],
[
168,
23,
1598
]
],
[
[
1468,
63,
594
],
[
594,
24,
1598
]
],
[
[
1468,
24,
738
],
[
738,
... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib... |
DB00758 | DB05578 | 1,347 | 330 | [
"DDInter413",
"DDInter1566"
] | Clopidogrel | Ramucirumab | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Major | 2 | [
[
[
1347,
25,
330
]
],
[
[
1347,
24,
41
],
[
41,
63,
330
]
],
[
[
1347,
24,
901
],
[
901,
24,
330
]
],
[
[
1347,
63,
1100
],
[
1100,
... | [
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"Le... | Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Milnacip... |
DB00366 | DB01043 | 1,594 | 108 | [
"DDInter600",
"DDInter1146"
] | Doxylamine | Memantine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in ... | Moderate | 1 | [
[
[
1594,
24,
108
]
],
[
[
1594,
18,
18226
],
[
18226,
57,
108
]
],
[
[
1594,
21,
28852
],
[
28852,
60,
108
]
],
[
[
1594,
24,
506
],
[
50... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Memantine"
]
],
[
[
"Doxylamine",
"{u} (Compound) downregulates {v} (Gene)",
"GDF15"
],
[
"GDF15",
"{u} (Gene) is downregulated by {v}... | Doxylamine (Compound) downregulates GDF15 (Gene) and GDF15 (Gene) is downregulated by Memantine (Compound)
Doxylamine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Memantine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dextr... |
DB00451 | DB00930 | 542 | 166 | [
"DDInter1064",
"DDInter432"
] | Levothyroxine | Colesevelam | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in th... | Moderate | 1 | [
[
[
542,
24,
166
]
],
[
[
542,
24,
959
],
[
959,
63,
166
]
],
[
[
542,
63,
1645
],
[
1645,
24,
166
]
],
[
[
542,
24,
126
],
[
126,
2... | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colesevelam"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Colesevelam
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Me... |
DB00790 | DB01069 | 664 | 401 | [
"DDInter1431",
"DDInter1533"
] | Perindopril | Promethazine | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
664,
24,
401
]
],
[
[
664,
24,
1264
],
[
1264,
63,
401
]
],
[
[
664,
24,
104
],
[
104,
24,
401
]
],
[
[
664,
6,
4973
],
[
4973,
... | [
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdi... |
DB00407 | DB08875 | 202 | 1,618 | [
"DDInter115",
"DDInter262"
] | Ardeparin | Cabozantinib | Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
202,
25,
1618
]
],
[
[
202,
25,
283
],
[
283,
63,
1618
]
],
[
[
202,
24,
222
],
[
222,
24,
1618
]
],
[
[
202,
24,
738
],
[
738,
... | [
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} m... | Ardeparin may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may caus... |
DB00372 | DB00813 | 999 | 704 | [
"DDInter1793",
"DDInter722"
] | Thiethylperazine | Fentanyl | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Moderate | 1 | [
[
[
999,
24,
704
]
],
[
[
999,
24,
194
],
[
194,
40,
704
]
],
[
[
999,
24,
543
],
[
543,
1,
704
]
],
[
[
999,
25,
675
],
[
675,
40,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin and Darifenacin (Compound) resembles Fentanyl (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide (Compound) resembles Fentanyl (... |
DB00290 | DB00446 | 329 | 597 | [
"DDInter219",
"DDInter351"
] | Bleomycin | Chloramphenicol | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Moderate | 1 | [
[
[
329,
24,
597
]
],
[
[
329,
21,
28787
],
[
28787,
60,
597
]
],
[
[
329,
24,
450
],
[
450,
62,
597
]
],
[
[
329,
63,
599
],
[
599,
... | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Bleomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is... | Bleomycin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Chloramphenicol (Compound)
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide may cause a minor interaction that can limit clinical effects when tak... |
DB01394 | DB08889 | 1,554 | 350 | [
"DDInter431",
"DDInter299"
] | Colchicine | Carfilzomib | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Moderate | 1 | [
[
[
1554,
24,
350
]
],
[
[
1554,
6,
4973
],
[
4973,
45,
350
]
],
[
[
1554,
21,
28762
],
[
28762,
60,
350
]
],
[
[
1554,
24,
310
],
[
310,
... | [
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Colchicine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Colchicine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Carfilzomib (Compound)
Colchicine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Carfilzomib (Compound)
Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabaz... |
DB06448 | DB11718 | 171 | 927 | [
"DDInter1087",
"DDInter640"
] | Lonafarnib | Encorafenib | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
171,
25,
927
]
],
[
[
171,
63,
112
],
[
112,
23,
927
]
],
[
[
171,
63,
1088
],
[
1088,
24,
927
]
],
[
[
171,
24,
659
],
[
659,
2... | [
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metron... | Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Rifaximin and Ri... |
DB00252 | DB09570 | 362 | 1,480 | [
"DDInter1460",
"DDInter1002"
] | Phenytoin | Ixazomib | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Major | 2 | [
[
[
362,
25,
1480
]
],
[
[
362,
24,
310
],
[
310,
24,
1480
]
],
[
[
362,
63,
1184
],
[
1184,
24,
1480
]
],
[
[
362,
1,
998
],
[
998,
... | [
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixazomib"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra m... |
DB00402 | DB01069 | 1,407 | 401 | [
"DDInter685",
"DDInter1533"
] | Eszopiclone | Promethazine | Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a ... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1407,
24,
401
]
],
[
[
1407,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1407,
24,
104
],
[
104,
24,
401
]
],
[
[
1407,
6,
6017
],
[
6017,
... | [
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdi... |
DB00022 | DB01095 | 268 | 671 | [
"DDInter1408",
"DDInter769"
] | Peginterferon alfa-2b | Fluvastatin | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Moderate | 1 | [
[
[
268,
24,
671
]
],
[
[
268,
24,
788
],
[
788,
40,
671
]
],
[
[
268,
24,
14
],
[
14,
63,
671
]
],
[
[
268,
24,
126
],
[
126,
23,
... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pita... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Fluvastatin (Compound)
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a ... |
DB00705 | DB01254 | 441 | 1,213 | [
"DDInter496",
"DDInter484"
] | Delavirdine | Dasatinib | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Major | 2 | [
[
[
441,
25,
1213
]
],
[
[
441,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
441,
21,
28882
],
[
28882,
60,
1213
]
],
[
[
441,
25,
1135
],
[
1135,... | [
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Delavirdine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dasati... | Delavirdine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Delavirdine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Delavirdine may lead to a major life threatening interaction when taken with... |
DB00427 | DB00996 | 1,233 | 1,198 | [
"DDInter1879",
"DDInter791"
] | Triprolidine | Gabapentin | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures[A186277,A186143] - today it is also widely used to tr... | Moderate | 1 | [
[
[
1233,
24,
1198
]
],
[
[
1233,
24,
1311
],
[
1311,
63,
1198
]
],
[
[
1233,
24,
530
],
[
530,
24,
1198
]
],
[
[
1233,
63,
1594
],
[
1594... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gabapentin"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Gabapentin
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Dronabino... |
DB00488 | DB01242 | 196 | 1,237 | [
"DDInter57",
"DDInter410"
] | Altretamine | Clomipramine | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
196,
24,
1237
]
],
[
[
196,
24,
1164
],
[
1164,
1,
1237
]
],
[
[
196,
63,
21
],
[
21,
1,
1237
]
],
[
[
196,
21,
28803
],
[
28803,
... | [
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
],
... | Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Clomipramine (Compound)
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline (Compound) resembles Clomipra... |
DB00876 | DB01240 | 1,414 | 885 | [
"DDInter658",
"DDInter657"
] | Eprosartan | Epoprostenol | Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced. | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
1414,
24,
885
]
],
[
[
1414,
63,
1061
],
[
1061,
1,
885
]
],
[
[
1414,
6,
6017
],
[
6017,
45,
885
]
],
[
[
1414,
21,
28936
],
[
28936,... | [
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Eprosartan (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Epoprostenol (Compound)
Eprosartan (Compound) causes Hyperhidrosis (Side Effect) a... |
DB00285 | DB00486 | 1,100 | 1,614 | [
"DDInter1927",
"DDInter1253"
] | Venlafaxine | Nabilone | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Moderate | 1 | [
[
[
1100,
24,
1614
]
],
[
[
1100,
24,
530
],
[
530,
1,
1614
]
],
[
[
1100,
21,
28789
],
[
28789,
60,
1614
]
],
[
[
1100,
24,
516
],
[
516,... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
... | Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Venlafaxine (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Nabilone (Compound)
Venlafaxine may cause ... |
DB00612 | DB00789 | 1,121 | 1,431 | [
"DDInter216",
"DDInter796"
] | Bisoprolol | Gadopentetic acid | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706) | Moderate | 1 | [
[
[
1121,
24,
1431
]
],
[
[
1121,
63,
457
],
[
457,
40,
1431
]
],
[
[
1121,
24,
808
],
[
808,
40,
1431
]
],
[
[
1121,
21,
28658
],
[
28658... | [
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadopentetic acid"
]
],
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadodiamide"
],
... | Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Gadodiamide and Gadodiamide (Compound) resembles Gadopentetic acid (Compound)
Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Gadobenic acid and Gadobenic acid (Compound) resembles Gadop... |
DB00060 | DB08886 | 912 | 637 | [
"DDInter947",
"DDInter126"
] | Interferon beta-1a | Asparaginase Erwinia chrysanthemi | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
912,
24,
637
]
],
[
[
912,
24,
640
],
[
640,
24,
637
]
],
[
[
912,
63,
491
],
[
491,
24,
637
]
],
[
[
912,
24,
250
],
[
250,
63,... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Acitretin and Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases ... |
DB00006 | DB12500 | 942 | 283 | [
"DDInter217",
"DDInter714"
] | Bivalirudin | Fedratinib | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
942,
25,
283
]
],
[
[
942,
24,
885
],
[
885,
24,
283
]
],
[
[
942,
25,
932
],
[
932,
24,
283
]
],
[
[
942,
25,
1564
],
[
1564,
2... | [
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epopro... | Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Bivalirudin may lead to a major life threatening interaction when taken with Mifepristone and Mifepristone ... |
DB00906 | DB11901 | 1,567 | 913 | [
"DDInter1801",
"DDInter107"
] | Tiagabine | Apalutamide | Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1567,
24,
913
]
],
[
[
1567,
63,
600
],
[
600,
24,
913
]
],
[
[
1567,
24,
1619
],
[
1619,
63,
913
]
],
[
[
1567,
24,
401
],
[
401,
... | [
[
[
"Tiagabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Tiagabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
... | Tiagabine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Tiagabine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucapa... |
DB00095 | DB01234 | 66 | 1,220 | [
"DDInter623",
"DDInter513"
] | Efalizumab | Dexamethasone | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
66,
24,
1220
]
],
[
[
66,
24,
870
],
[
870,
1,
1220
]
],
[
[
66,
24,
175
],
[
175,
40,
1220
]
],
[
[
66,
23,
1461
],
[
1461,
23,... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dex... |
DB01177 | DB01610 | 77 | 248 | [
"DDInter904",
"DDInter1912"
] | Idarubicin | Valganciclovir | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
77,
24,
248
]
],
[
[
77,
63,
563
],
[
563,
1,
248
]
],
[
[
77,
21,
29209
],
[
29209,
60,
248
]
],
[
[
77,
63,
1238
],
[
1238,
24... | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
... | Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound)
Idarubicin (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Valganciclovir (Compound)
Idarubicin may cause a moderate inte... |
DB00927 | DB00934 | 1,559 | 413 | [
"DDInter712",
"DDInter1124"
] | Famotidine | Maprotiline | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does n... | Moderate | 1 | [
[
[
1559,
24,
413
]
],
[
[
1559,
63,
1302
],
[
1302,
40,
413
]
],
[
[
1559,
63,
847
],
[
847,
1,
413
]
],
[
[
1559,
18,
4930
],
[
4930,
... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maprotiline"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protriptyline"
],
... | Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Maprotiline (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Maprotiline (... |
DB00204 | DB09330 | 228 | 985 | [
"DDInter580",
"DDInter1352"
] | Dofetilide | Osimertinib | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
228,
25,
985
]
],
[
[
228,
23,
112
],
[
112,
23,
985
]
],
[
[
228,
25,
608
],
[
608,
23,
985
]
],
[
[
228,
24,
1478
],
[
1478,
2... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Dofetilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Dofetilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Dofetilide may lead to a major life threatening interaction when taken with Lidocaine and Lidocaine may cause... |
DB01155 | DB14520 | 872 | 1,229 | [
"DDInter813",
"DDInter1785"
] | Gemifloxacin | Tetraferric tricitrate decahydrate | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014. | Moderate | 1 | [
[
[
872,
24,
1229
]
],
[
[
872,
63,
1096
],
[
1096,
23,
1229
]
],
[
[
872,
40,
246
],
[
246,
24,
1229
]
],
[
[
872,
1,
945
],
[
945,
... | [
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Tetraferric tricitrate decahydrate
Gemifloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin... |
DB01268 | DB06788 | 1,151 | 1,616 | [
"DDInter1731",
"DDInter864"
] | Sunitinib | Histrelin | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
1151,
24,
1616
]
],
[
[
1151,
62,
112
],
[
112,
23,
1616
]
],
[
[
1151,
63,
1664
],
[
1664,
24,
1616
]
],
[
[
1151,
24,
1342
],
[
1342... | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Sunitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Sunitinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risper... |
DB04948 | DB06589 | 1,084 | 1,250 | [
"DDInter1083",
"DDInter1400"
] | Lofexidine | Pazopanib | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
1084,
24,
1250
]
],
[
[
1084,
62,
112
],
[
112,
23,
1250
]
],
[
[
1084,
63,
1151
],
[
1151,
24,
1250
]
],
[
[
1084,
24,
28
],
[
28,
... | [
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Lofexidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Lofexidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pazopanib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Suniti... |
DB00252 | DB01234 | 362 | 1,220 | [
"DDInter1460",
"DDInter513"
] | Phenytoin | Dexamethasone | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
362,
24,
1220
]
],
[
[
362,
24,
870
],
[
870,
1,
1220
]
],
[
[
362,
24,
175
],
[
175,
40,
1220
]
],
[
[
362,
6,
21998
],
[
21998,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexam... |
DB00860 | DB01357 | 891 | 890 | [
"DDInter1513",
"DDInter1160"
] | Prednisolone | Mestranol | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. | Moderate | 1 | [
[
[
891,
24,
890
]
],
[
[
891,
24,
35
],
[
35,
40,
890
]
],
[
[
891,
63,
380
],
[
380,
40,
890
]
],
[
[
891,
35,
1546
],
[
1546,
40,... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
],
[... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol and Quinestrol (Compound) resembles Mestranol (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens (Compound) resembles... |
DB01041 | DB12825 | 770 | 1,375 | [
"DDInter1789",
"DDInter1032"
] | Thalidomide | Lefamulin | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
770,
24,
1375
]
],
[
[
770,
63,
112
],
[
112,
23,
1375
]
],
[
[
770,
25,
1532
],
[
1532,
24,
1375
]
],
[
[
770,
24,
309
],
[
309,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Thalidomide may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide may c... |
DB00585 | DB01124 | 1,127 | 1,411 | [
"DDInter1309",
"DDInter1828"
] | Nizatidine | Tolbutamide | A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
1127,
24,
1411
]
],
[
[
1127,
24,
959
],
[
959,
40,
1411
]
],
[
[
1127,
63,
245
],
[
245,
40,
1411
]
],
[
[
1127,
18,
5818
],
[
5818,
... | [
[
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound... |
DB01168 | DB08880 | 1,053 | 1,510 | [
"DDInter1526",
"DDInter1771"
] | Procarbazine | Teriflunomide | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1053,
25,
1510
]
],
[
[
1053,
63,
1461
],
[
1461,
23,
1510
]
],
[
[
1053,
24,
221
],
[
221,
63,
1510
]
],
[
[
1053,
24,
1136
],
[
1136... | [
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vita... | Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.